Circulating Collagen Biomarkers as Indicators of Disease Severity in Pulmonary Arterial Hypertension

JACC: Heart Failure

Volumn 2, Issue 4, 2014, Pages 412-421

  Safdar, Zeenat ^a   Tamez, Emilio ^a   Chan, Wenyaw ^b   Arya, Basant ^c   Ge, Yimin ^a   Deswal, Anita ^c   Bozkurt, Biykem ^c   Frost, Adaani ^a   Entman, Mark ^c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

BNP; Heart failure; PIIINP; Vascular remodeling

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PROPEPTIDE OF TYPE III PROCOLLAGEN; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CARBOXY TERMINAL TELOPEPTIDE OF COLLAGEN TYPE I; CARDIAC GLYCOSIDE; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; GELATINASE B; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE;

6 MINUTE WALK DISTANCE; ADULT; ARTICLE; BORG DYSPNEA SCORE; COLLAGEN METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEALTH STATUS INDICATOR; HEART FUNCTION TEST; HEART INDEX; HEART LUNG TRANSPLANTATION; HEART RIGHT ATRIUM PRESSURE; HEART VENTRICLE REMODELING; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; OXYGEN SATURATION; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RESTING HEART RATE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; WORLD HEALTH ORGANIZATION FUNCTIONAL CLASSIFICATION; CROSS-SECTIONAL STUDY; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HYPERTENSION, PULMONARY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

BIOLOGICAL MARKERS; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PERICARDIAL EFFUSION; PROCOLLAGEN; PROGNOSIS; PROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84905442731     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.03.013     Document Type: Article

References (35)

1. Fessler J.H., Fessler L.I. Biosynthesis of procollagen. Annu Rev Biochem 1978, 47:129-162.
2. Rojkind M, editor. Connective Tissue in Health and Disease. Boca Raton, FL: Taylor & Francis Group, 1990.
3. Bergers G., Brekken R., McMahon G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744.
4. Nikolova A., Ablasser K., Wyler von Ballmoos M.C., et al. Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy. Ann Thorac Surg 2012, 94:1509-1517.
5. Cuenca J., Martin-Sanz P., Alvarez-Barrientos A.M., Bosca L., Goren N. Infiltration of inflammatory cells plays an important role in matrix metalloproteinase expression and activation in the heart during sepsis. Am J Pathol 2006, 169:1567-1576.
6. Stintzing S., Heuschmann P., Barbera L., et al. Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosis. Ann Vasc Surg 2005, 19:310-319.
7. Botney M.D., Liptay M.J., Kaiser L.R., Cooper J.D., Parks W.C., Mecham R.P. Active collagen synthesis by pulmonary arteries in human primary pulmonary hypertension. Am J Pathol 1993, 143:121-129.
8. Botney M.D., Kaiser L.R., Cooper J.D., et al. Extracellular matrix protein gene expression in atherosclerotic hypertensive pulmonary arteries. Am J Pathol 1992, 140:357-364.
9. Harrison N.K., Laurent G.J., Evans T.W. Transpulmonary gradient of type III procollagen peptides: acute effects of cardio-pulmonary bypass. Intensive Care Med 1992, 18:290-292.
10. Pohl W.R., Thompson A.B., Kohn H., et al. Serum procollagen III peptide levels in subjects with sarcoidosis. A 5-year follow-up study. Am Rev Respir Dis 1992, 145:412-417.
11. Low R.B., Giancola M.S., King T.E., Chapitis J., Vacek P., Davis G.S. Serum and bronchoalveolar lavage of N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1992, 146:701-706.
12. Bentsen K.D., Nielsen T.L. Eaftinck Schattenkerk JK, Jensen BN, Lundgren JD. Serum type III procollagen peptide in patients with Pneumocystis carinii infection. The Copenhagen-Amsterdam PCP-Prednisolone Study Group. Am Rev Respir Dis 1993, 148:1558-1562.
13. Chesnutt A.N., Matthay M.A., Tibayan F.A., Clark J.G. Early detection of type III procollagen peptide in acute lung injury. Pathogenetic and prognostic significance. Am J Respir Crit Care Med 1997, 156:840-845.
14. Entzian P., Huckstadt A., Kreipe H., Barth J. Determination of serum concentrations of type III procollagen peptide in mechanically ventilated patients. Pronounced augmented concentrations in the adult respiratory distress syndrome. Am Rev Respir Dis 1990, 142:1079-1082.
15. Meduri G.U., Tolley E.A., Chinn A., Stentz F., Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998, 158:1432-1441.
16. McLaughlin V.V., McGoon M.D. Pulmonary arterial hypertension. Circulation 2006, 114:1417-1431.
17. Rudski L.G., Lai W.W., Afilalo J., et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010, 23:685-713. quiz 786-8.
18. Hardziyenka M., Reesink H.J., Bouma B.J., et al. A novel echocardiographic predictor of in-hospital mortality and mid-term haemodynamic improvement after pulmonary endarterectomy for chronic thrombo-embolic pulmonary hypertension. Eur Heart J 2007, 28:842-849.
19. Badesch D.B., Abman S.H., Simonneau G., Rubin L.J., McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007, 131:1917-1928.
20. Barst R.J., Galie N., Naeije R., et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006, 28:1195-1203.
21. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006, 173:1023-1030.
22. Deng W., Chen Q.W., Li G.Q., et al. Procollagen III N-terminal peptide predicts short-term prognosis and cardiac remodeling in coronary heart disease patients with metabolic syndrome. Am J Med Sci 2011, 341:10-16.
23. Agrinier N., Thilly N., Boivin J.M., Dousset B., Alla F., Zannad F. Prognostic value of serum PIIINP, MMP1 and TIMP1 levels in hypertensive patients: a community-based prospective cohort study. Fundam Clin Pharmacol 2013, 27:572-580.
24. Gonzalez A., Lopez B., Querejeta R., Zubillaga E., Echeverria T., Diez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010, 55:1418-1424.
25. Iraqi W., Rossignol P., Angioi M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009, 119:2471-2479.
26. Izawa H., Murohara T., Nagata K., et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005, 112:2940-2945.
27. Bishop J.E., Rhodes S., Laurent G.J., Low R.B., Stirewalt W.S. Increased collagen synthesis and decreased collagen degradation in right ventricular hypertrophy induced by pressure overload. Cardiovasc Res 1994, 28:1581-1585.
28. Chen C.A., Tseng W.Y., Wang J.K., et al. Circulating biomarkers of collagen type I metabolism mark the right ventricular fibrosis and adverse markers of clinical outcome in adults with repaired tetralogy of Fallot. Int J Cardiol 2013, 167:2963-2968.
29. Turner J.E., Oliver M.H., Guerreiro D., Laurent G.J. Collagen metabolism during right ventricular hypertrophy following induced lung injury. Am J Physiol 1986, 251:H915-H919.
30. Gardi C., Martorana P.A., Calzoni P., et al. Cardiac collagen changes during the development of right ventricular hypertrophy in tight-skin mice with emphysema. Exp Mol Pathol 1994, 60:100-107.
31. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102:865-870.
32. Yoshimura M., Yasue H., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993, 87:464-469.
33. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998, 31:202-208.
34. Leuchte H.H., Holzapfel M., Baumgartner R.A., et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004, 43:764-770.
35. Marchesi C., Essalmani R., Lemarie C.A., et al. Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: role of fibroblast autophagy. J Mol Med (Berl) 2011, 89:1103-1111.